Small surface antigen variants of HBV associated with responses to telbivudine treatment in chronic hepatitis B patients
文献类型：期刊论文
| 作者 | Dong, Hui6; Jin, Weirong6; Zhu, Yongqiang6; Wang, Shengyue6; Zhao, Guoping6; Zhou, Bin7; Sun, Jian7; Hou, Jinlin7; Kang, Hui8; Jin, Weirong9 |
| 刊名 | ANTIVIRAL THERAPY
 |
| 出版日期 | 2017 |
| 卷号 | 22期号:1页码:43-51 |
| ISSN号 | 1359-6535 |
| DOI | 10.3851/IMP3078 |
| 文献子类 | Article |
| 英文摘要 | Background: Nucleoside/nucleotide analogues are widely used to treat chronic HBV infection, but drug resistance is common. The role of HBV surface gene variants in drug resistance to nucleoside/nucleotide analogues is unknown. We are trying to investigate the dynamics of S gene mutations and how they relate to a patient's virological response in this study. Methods: Thirty patients with chronic hepatitis B were enrolled and serum samples were collected at multiple time points during treatment with telbivudine (LdT). The coding regions of the small surface antigen (S-HBsAg) were amplified and sequenced using the 454 GS FLX+ System. Results: Sequencing results revealed different dynamics of non-synonymous mutations, such as sL9P, sN40S, sG44E, sW172*, sW182* and sS187F, between patients with a complete virological response and those with a partial virological response. The viral population heterogeneity decreased at week 12 of LdT treatment in patients with a complete virological response, with a concomitant decline in non-synonymous mutations (from an average of 14 to 9.9 per sample) and an increase in the frequencies of major variants (from 14.3% to 40.4%). Conclusions: Our findings suggest that the decrease in viral population heterogeneity at an early stage of LdT treatment was associated with the subsequent optimal virological response, and the early appearance of some specific mutations, such as sG44E, sW172* and sW182*, is a potential indicator of a partial virological response in continuing therapy. |
| 学科主题 | Infectious Diseases ; Pharmacology & Pharmacy ; Virology |
| WOS关键词 | LAMIVUDINE THERAPY ; ADEFOVIR DIPIVOXIL ; VIRAL-HEPATITIS ; VIRUS-INFECTION ; RESISTANCE ; MUTATION ; POLYMERASE ; IMPACT ; SECRETION ; SELECTION |
| 语种 | 英语 |
| WOS记录号 | WOS:000396497300005 |
| 出版者 | INT MEDICAL PRESS LTD |
| 版本 | 出版稿 |
| 源URL | [http://202.127.25.144/handle/331004/1092]  |
| 专题 | 中国科学院上海生命科学研究院营养科学研究所 |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Plant Physiol & Ecol, CAS Key Lab Synthet Biol, Shanghai, Peoples R China; 2.Chinese Univ Hong Kong, Prince Wales Hosp, Dept Microbiol, Hong Kong, Hong Kong, Peoples R China; 3.Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; 4.Chinese Acad Sci, Shanghai Inst Biol Sci, CAS MPG Partner Inst Computat Biol, CAS Key Lab Computat Biol, Shanghai, Peoples R China, 5.Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Zhejiang, Peoples R China; 6.Chinese Natl Human Genome Ctr Shanghai, Shanghai MOST Key Lab Hlth & Dis Genom, Shanghai, Peoples R China; 7.Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangdong Prov Key Lab Viral Hepatitis Res,State, Guangzhou, Guangdong, Peoples R China; 8.Fudan Univ, Sch Life Sci, Shanghai, Peoples R China; 9.Shanghai Shenyou Biotechnol Co Ltd, Shanghai, Peoples R China; |
| 推荐引用方式 GB/T 7714 | Dong, Hui,Jin, Weirong,Zhu, Yongqiang,et al. Small surface antigen variants of HBV associated with responses to telbivudine treatment in chronic hepatitis B patients[J]. ANTIVIRAL THERAPY,2017,22(1):43-51. |
| APA | Dong, Hui.,Jin, Weirong.,Zhu, Yongqiang.,Wang, Shengyue.,Zhao, Guoping.,...&,.(2017).Small surface antigen variants of HBV associated with responses to telbivudine treatment in chronic hepatitis B patients.ANTIVIRAL THERAPY,22(1),43-51. |
| MLA | Dong, Hui,et al."Small surface antigen variants of HBV associated with responses to telbivudine treatment in chronic hepatitis B patients".ANTIVIRAL THERAPY 22.1(2017):43-51. |
入库方式： OAI收割
来源：上海营养与健康研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。